BiotechTube

Panobinostat + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin's Lymphoma

Conditions

Hodgkin's Lymphoma

Trial Timeline

Jun 1, 2010 → May 1, 2012

NCT ID
NCT01034163

About Panobinostat + Placebo

Panobinostat + Placebo is a phase 3 stage product being developed by Novartis for Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01034163. Target conditions include Hodgkin's Lymphoma.

What happened to similar drugs?

8 of 20 similar drugs in Hodgkin's Lymphoma were approved

Approved (8) Terminated (2) Active (10)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01034163Phase 3Completed

Competing Products

20 competing products in Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
R-mabHD + ABVDEli LillyPhase 2
31
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21